$ATRA
Atara Biotherapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021054261 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q2 2020 Q1
Revenue $5.370M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.85M $16.39M $17.04M
YoY Change 33.84% -29.6% -11.34%
% of Gross Profit
Research & Development $70.33M $61.56M $57.66M
YoY Change 17.46% 17.82% 18.47%
% of Gross Profit
Depreciation & Amortization $2.317M $2.050M $1.950M
YoY Change 6.28% 17.82% 18.18%
% of Gross Profit
Operating Expenses $90.18M $77.95M $74.70M
YoY Change 20.71% 3.2% 10.03%
Operating Profit -$84.81M -$77.95M
YoY Change 3.2%
Interest Expense $148.0K $500.0K $1.190M
YoY Change -58.89% -58.68% -26.99%
% of Operating Profit
Other Income/Expense, Net $148.0K $497.0K $1.188M
YoY Change -58.82% -27.29%
Pretax Income -$84.66M -$77.46M -$73.51M
YoY Change 13.89% 4.21% 10.94%
Income Tax $0.00 $1.000K
% Of Pretax Income
Net Earnings -$84.66M -$77.46M -$73.51M
YoY Change 13.88% 4.21% 10.95%
Net Earnings / Revenue -1576.61%
Basic Earnings Per Share -$0.90
Diluted Earnings Per Share -$904.5K -$1.139M -$1.201M
COMMON SHARES
Basic Shares Outstanding 93.60M
Diluted Shares Outstanding 93.60M

Balance Sheet

Concept 2021 Q3 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $357.2M $347.7M $214.6M
YoY Change 9.18% 82.9% -9.64%
Cash & Equivalents $113.2M $75.91M $70.20M
Short-Term Investments $244.0M $273.2M $144.4M
Other Short-Term Assets $12.25M $11.30M $14.60M
YoY Change -0.39% 2.73% 9.77%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $369.5M $359.0M $229.2M
YoY Change 8.87% 78.48% -8.61%
LONG-TERM ASSETS
Property, Plant & Equipment $53.49M $53.59M $54.44M
YoY Change 2.95% -6.14% -24.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.870M $2.200M $2.200M
YoY Change -10.95% 589.66% 29.41%
Total Long-Term Assets $80.43M $69.10M $70.30M
YoY Change 21.67% -5.35% -4.87%
TOTAL ASSETS
Total Short-Term Assets $369.5M $359.0M $229.2M
Total Long-Term Assets $80.43M $69.10M $70.30M
Total Assets $449.9M $428.1M $299.5M
YoY Change 10.96% 56.16% -7.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.54M $5.100M $8.100M
YoY Change 218.13% -20.56% 30.65%
Accrued Expenses $29.11M $20.90M $17.50M
YoY Change 13.73% 50.36% 22.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $86.15M $31.70M $31.50M
YoY Change 138.64% 22.85% 25.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $53.63M $15.30M $15.20M
YoY Change 246.01% 1238.58% 1188.14%
Total Long-Term Liabilities $53.63M $15.30M $15.20M
YoY Change 246.01% 1238.58% 1188.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.15M $31.70M $31.50M
Total Long-Term Liabilities $53.63M $15.30M $15.20M
Total Liabilities $139.8M $47.00M $46.70M
YoY Change 170.9% 12.27% 14.48%
SHAREHOLDERS EQUITY
Retained Earnings -$968.9M -$891.5M
YoY Change 45.13% 50.28%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $310.1M $381.1M $252.8M
YoY Change
Total Liabilities & Shareholders Equity $449.9M $428.1M $299.5M
YoY Change 10.96% 56.16% -7.77%

Cashflow Statement

Concept 2021 Q3 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$84.66M -$77.46M -$73.51M
YoY Change 13.88% 4.21% 10.95%
Depreciation, Depletion And Amortization $2.317M $2.050M $1.950M
YoY Change 6.28% 17.82% 18.18%
Cash From Operating Activities -$58.98M -$56.64M -$67.04M
YoY Change 11.36% 3.76% -4.5%
INVESTING ACTIVITIES
Capital Expenditures -$3.856M -$2.080M $1.333M
YoY Change 671.2% 184.93% 67.46%
Acquisitions
YoY Change
Other Investing Activities $5.050M -$128.3M $40.31M
YoY Change -37.42% -351.62% -41.06%
Cash From Investing Activities $1.194M -$130.4M $38.97M
YoY Change -84.21% -359.44% -42.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.28M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.14M 191.3M 23.96M
YoY Change 40.67% 2509.96% -1343.87%
NET CHANGE
Cash From Operating Activities -58.98M -56.64M -67.04M
Cash From Investing Activities 1.194M -130.4M 38.97M
Cash From Financing Activities 47.14M 191.3M 23.96M
Net Change In Cash -10.65M 4.300M -4.114M
YoY Change -10.45% 43.81% -9.18%
FREE CASH FLOW
Cash From Operating Activities -$58.98M -$56.64M -$67.04M
Capital Expenditures -$3.856M -$2.080M $1.333M
Free Cash Flow -$55.12M -$54.56M -$68.38M
YoY Change 5.07% 1.3% -3.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-78335000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
399037000
CY2020Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1330000
CY2020Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1904000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1231000
CY2021Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1749000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12268000
CY2021Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
2599000
CY2021Q3 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
842000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13762000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-84664000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-38000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
310141000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1395000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12644000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
252822000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13948000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-77456000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
209000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8710000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2718000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1318000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2004000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
606000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
381125000
CY2020Q3 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
185000
us-gaap Profit Loss
ProfitLoss
-246792000
us-gaap Profit Loss
ProfitLoss
-225313000
us-gaap Share Based Compensation
ShareBasedCompensation
39837000
us-gaap Share Based Compensation
ShareBasedCompensation
39847000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6857000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6175000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1251000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-458000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1275000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1100000
us-gaap Accretion Expense
AccretionExpense
64000
us-gaap Accretion Expense
AccretionExpense
58000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1250000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10841000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-717000
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
0
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-886000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-5839000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
542000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1859000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-459000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3182000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46582000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83836000
atra Proceeds From Issuance Of Underwritten Public Offering
ProceedsFromIssuanceOfUnderwrittenPublicOffering
0
atra Proceeds From Issuance Of Underwritten Public Offering
ProceedsFromIssuanceOfUnderwrittenPublicOffering
189301000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
atra Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
2344000
atra Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
254000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13427000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
atra Receivable For Options Exercised
ReceivableForOptionsExercised
0
atra Receivable For Options Exercised
ReceivableForOptionsExercised
12000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48739000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58045000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5190000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3407000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1244000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1521000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
192000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
289000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-17000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14253437
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11316174
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
499049000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
499345000
CY2021Q3 us-gaap Interest Receivable
InterestReceivable
400000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
700000
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1400000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
299282000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
299320000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
434828000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
435023000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
55752000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
55738000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
64221000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
64322000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
355034000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
355058000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113209000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200404000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114603000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201798000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79808000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70193000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26323000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19676000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53485000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50517000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2300000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6200000
CY2021Q3 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2021Q3 atra Accrued Termination Charges
AccruedTerminationCharges
600000
CY2020Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2021Q3 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2021Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21441111
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13762000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13255000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39837000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39847000

Files In Submission

Name View Source Status
0001564590-21-054261-index-headers.html Edgar Link pending
0001564590-21-054261-index.html Edgar Link pending
0001564590-21-054261.txt Edgar Link pending
0001564590-21-054261-xbrl.zip Edgar Link pending
atra-10q_20210930.htm Edgar Link pending
atra-10q_20210930_htm.xml Edgar Link completed
atra-20210930.xsd Edgar Link pending
atra-20210930_cal.xml Edgar Link unprocessable
atra-20210930_def.xml Edgar Link unprocessable
atra-20210930_lab.xml Edgar Link unprocessable
atra-20210930_pre.xml Edgar Link unprocessable
atra-ex101_82.htm Edgar Link pending
atra-ex311_8.htm Edgar Link pending
atra-ex312_7.htm Edgar Link pending
atra-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending